Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Medivation Inc    MDVN

Delayed Quote. Delayed  - 08/31 10:00:00 pm
80.56 USD   +0.25%
08/31 GOP TO HIGH COU : Hold McAuliffe in contempt
08/31 PFIZER : Seven Hampton schools get 'mini-makeovers' this summer
08/29 A $510,000 tab to clean Chase Bag site
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Medivation Inc : Medivation Announces Participation at Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/30/2013 | 10:34pm CEST

SAN FRANCISCO, CA -- (Marketwired) -- 10/28/13 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss third quarter 2013 financial results and provide a general business update on November 12, 2013 at 4:30 p.m. Eastern Time. A press release for the third quarter of 2013 will be released after markets close on November 12, 2013.

Interested parties may listen to the live teleconference by calling 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals may access the live audio webcast by visiting: http://investors.medivation.com/events.cfm.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.

Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900

Source: Medivation

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVATION INC
08/31 GOP TO HIGH COURT : Hold McAuliffe in contempt
08/31 PFIZER : Seven Hampton schools get 'mini-makeovers' this summer
08/29 A $510,000 tab to clean Chase Bag site
08/29 PFIZER : Cypress Creek Bridge could see repairs, partial shutdown in 2020
08/29 PFIZER : IW Chamber offering free consultations for small business owners
08/28 PFIZER : Reports detail reasons why Eastern State lost its Medicare funding
08/27 PFIZER : Swimming advisory on two Newport News beaches lifted
08/27 PFIZER : Hampton is persistent, but can't land vet center
08/26 Children's Hospital of The King's Daughters wants to build clinic at City Cen..
08/26 Peninsula not giving up on launching new businesses
More news
Sector news : Bio Therapeutic Drugs
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJNOVARTIS : FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/31 Welcome To REIT Day
08/31 Market Needs To Consolidate - Cramer's Mad Money (8/30/16)
08/30 Is Gilead Sciences A Bargain?
08/29 BIOTECH FORUM DAILY DIGEST : Mylan Adjusts Course, Who Is Next Midcap Buyout Tar..
08/26 Updating My Price Target On Pfizer
Advertisement
Financials ($)
Sales 2016 907 M
EBIT 2016 336 M
Net income 2016 -279 M
Finance 2016 217 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 46,70
EV / Sales 2016 14,5x
EV / Sales 2017 11,1x
Capitalization 13 334 M
More Financials
Chart MEDIVATION INC
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Full-screen chart
Technical analysis trends MEDIVATION INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 77,2 $
Spread / Average Target -4,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David T. Hung President, Chief Executive Officer & Director
Kim D. Blickenstaff Chairman
Marion McCourt Chief Operating Officer
Jennifer Jarrett Chief Financial Officer
Mohammad Hirmand Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVATION INC66.24%13 334
AMGEN, INC.5.19%127 790
GILEAD SCIENCES, INC.-23.00%102 828
CELGENE CORPORATION-10.64%82 953
REGENERON PHARMACEUTIC..-27.20%41 614
VERTEX PHARMACEUTICALS..-23.87%23 737
More Results